Drug Delivery
Principles and Applications
Wiley series in drug discovery and development
2. Auflage Mai 2016
720 Seiten, Hardcover
Wiley & Sons Ltd
ISBN:
978-1-118-83336-0
John Wiley & Sons
Kurzbeschreibung
Following its successful predecessor, this book covers the fundamentals, delivery routes and vehicles, and practical applications of drug delivery. While almost all chapters from the prior edition are retained and updated, several new chapters are added to make a more complete resource and reference. New chapters cover recent developments including transdermal and mucosal delivery, nanoparticles, controlled drug release, lymphatic system delivery, theranostics, protein and peptide drugs, and biologics delivery.
Following its successful predecessor, this book covers the fundamentals, delivery routes and vehicles, and practical applications of drug delivery. In the 2nd edition, almost all chapters from the previous are retained and updated and several new chapters added to make a more complete resource and reference.
* Helps readers understand progress in drug delivery research and applications
* Updates and expands coverage to reflect advances in materials for delivery vehicles, drug delivery approaches, and therapeutics
* Covers recent developments including transdermal and mucosal delivery, lymphatic system delivery, theranostics
* Adds new chapters on nanoparticles, controlled drug release systems, theranostics, protein and peptide drugs, and biologics delivery
List of Contributors xvii
Preface xxi
1 Factors that Impact the Developability of Drug Candidates 1
Chao Han and Binghe Wang
1.1 Challenges Facing the Pharmaceutical Industry 1
1.2 Factors that Impact Developability 5
1.3 Remarks on Developability 12
1.4 Drug Delivery Factors that Impact Developability 13
References 15
2 Physiological, Biochemical, and Chemical Barriers to Oral Drug Delivery 19
Paul Kiptoo, Anna M. Calcagno, and Teruna J. Siahaan
2.1 Introduction 19
2.2 Physiological Barriers to Drug Delivery 20
2.3 Biochemical Barriers to Drug Delivery 25
2.4 Chemical Barriers to Drug Delivery 28
2.5 Drug Modifications to Enhance Transport Across Biological Barriers 29
2.6 Conclusions 31
Acknowledgment 31
References 31
3 Physicochemical Properties, Formulation, and Drug Delivery 35
Dewey H. Barich, Mark T. Zell, and Eric J. Munson
3.1 Introduction 35
3.2 Physicochemical Properties 36
3.3 Formulations 42
3.4 Drug Delivery 43
3.5 Conclusion 47
References 47
4 Targeted Bioavailability: A Fresh Look at Pharmacokinetic and Pharmacodynamic Issues in Drug Discovery and Development 49
Christine Xu
4.1 Introduction 49
4.2 Target Bioavailability 50
4.3 Drug Delivery Trends and Targets Related to PK and PD 51
4.4 PK-PD in Drug Discovery and Development 51
4.5 Source of Variability of Drug Response 55
4.6 Recent Development and Issues of Bio?]Analytical Methodology 57
4.7 Mechanistic PK-PD Models 58
4.8 Summary 60
References 60
5 The Role of Transporters in Drug Delivery and Excretion 62
Marilyn E. Morris and Xiaowen Guan
5.1 Introduction 62
5.2 Drug Transport in Absorption and Excretion 63
5.3 ABC (ATP?]Binding Cassette) Transporter Family 67
5.4 SlC (Solute Carrier) Transporter Family 76
5.5 Conclusions 88
Acknowledgment 88
References 89
6 Intracellular Delivery and Disposition of Small?]Molecular?]Weight Drugs 103
Jeffrey P. Krise
6.1 Introduction 103
6.2 The Relationship between the Intracellular Distribution of a Drug and its Activity 104
6.3 The Relationship between the Intracellular Distribution of a Drug and its Pharmacokinetic Properties 104
6.4 Overview of Approaches to Study Intracellular Drug Disposition 105
6.5 The Accumulation of Drugs in Mitochondria, Lysosomes, and Nuclei 108
6.6 Summary and Future Directions 123
References 124
7 Cell Culture Models for Drug Transport Studies 131
Irina Kalashnikova, Norah Albekairi, Shariq Ali, Sanaalarab Al Enazy, and Erik Rytting
7.1 Introduction 131
7.2 General Considerations 132
7.3 Intestinal Epithelium 133
7.4 The Blood-Brain Barrier 135
7.5 Nasal and Pulmonary Epithelium 137
7.6 The Ocular Epithelial and Endothelial Barriers 141
7.7 The Placental Barrier 142
7.8 The Renal Epithelium 143
7.9 3D In Vitro Models 145
7.10 Conclusions 146
References 146
8 Intellectual Property and Regulatory Issues in Drug Delivery Research 152
Shahnam Sharareh and Wansheng Jerry Liu
8.1 Introduction 152
8.2 Pharmaceutical Patents 153
8.3 Statutory Requirements for Obtaining a Patent 154
8.4 Patent Procurement Strategies 157
8.5 Regulatory Regime 158
8.6 FDA Market Exclusivities 160
8.7 Regulatory and Patent Law Linkage 162
References 162
9 Presystemic and First?]Pass Metabolism 164
Qingping Wang and Meng Li
9.1 Introduction 164
9.2 Hepatic First?]Pass Metabolism 165
9.3 Intestinal First?]Pass Metabolism 170
9.4 Prediction of First?]Pass Metabolism 174
9.5 S trategies for Optimization of Oral Bioavailability 178
9.6 Summary 179
References 180
10 Pulmonary Drug Delivery: Pharmaceutical Chemistry and Aerosol Technology 186
Anthony J. Hickey
10.1 Introduction 186
10.2 Aerosol Technology 187
10.3 Disease Therapy 190
10.4 Formulation Variables 196
10.5 Regulatory Considerations 200
10.6 Future Developments 201
10.7 Conclusion 201
References 202
11 Transdermal Delivery of Drugs Using Patches and Patchless Delivery Systems 207
Tannaz Ramezanli, Krizia Karry, Zheng Zhang, Kishore Shah, and Bozena Michniak?]Kohn
11.1 Introduction 207
11.2 Transdermal Patch Delivery Systems 208
11.3 Patchless Transdermal Drug Delivery Systems 211
11.4 Recent Advances in Transdermal Drug Delivery 216
11.5 Summary 221
References 222
12 Prodrug Approaches to Drug Delivery 227
Longqin Hu
12.1 Introduction 227
12.2 Basic Concepts: Definition and Applications 228
12.3 Prodrug Design Considerations 238
12.4 Prodrugs of Various Functional Groups 241
12.5 Drug Release and Activation Mechanisms 258
12.6 Prodrugs and Intellectual Property Rights--Two Court Cases 266
References 268
13 Liposomes as Drug Delivery Vehicles 272
Guijun Wang
13.1 Introduction 272
13.2 Currently Approved Liposomal Drugs in Clinical Applications 273
13.3 Conventional and Stealth Liposomes 276
13.4 Stimuli?]Responsive Liposomes or Triggered?]Release Liposomes 277
13.5 Targeted Liposomal Delivery 289
13.6 Hybrid Liposome Drug Delivery System 291
13.7 Conclusions and Future Perspectives 293
References 293
14 Nanoparticles as Drug Delivery Vehicles 299
Dan Menasco and Qian Wang
14.1 Introduction 299
14.2 O rganic DDVs 308
14.3 Inorganic DDVs: Metal?] and Silica?]Based Systems 320
14.4 Conclusion 330
References 330
15 Evolution of Controlled Drug Delivery Systems 336
Krishnaveni Janapareddi, Bhaskara R. Jasti, and Xiaoling Li
15.1 Introduction 336
15.2 Biopharmaceutics and Pharmacokinetics 337
15.3 Material Science 341
15.4 Proteins, Peptides and Nucleic Acids 343
15.5 Discovery of New Molecular Targets--Targeted Drug Delivery 345
15.6 Microelectronics and Microfabrication Technologies 347
15.7 Conclusion 349
References 349
16 Pathways for Drug Delivery to the Central Nervous System 353
Ngoc H. On, Vinith Yathindranath, Zhizhi Sun, and Donald W. Miller
16.1 Introduction 353
16.2 Circumventing the CNS Barriers 356
16.3 Transient BBB Disruption 359
16.4 Transcellular Delivery Routes 364
16.5 Conclusions 375
References 375
17 Metabolic Activation and Drug Targeting 383
Xiangming Guan
17.1 Introduction 383
17.2 Anticancer Prodrugs and their Biochemical Basis 384
17.3 Antibody?] and Gene?]Directed Enzyme Prodrug Therapy 420
17.4 Summary 429
References 429
18 Targeted Delivery of Drugs to the Colon 435
Anil K. Philip and Sarah K. Zingales
18.1 Introduction 435
18.2 Microbially Triggered Release 437
18.3 pH?]Sensitive Polymers for Time?]Dependent Release 442
18.4 Osmotic Release 443
18.5 Pressure?]Controlled Delivery 443
18.6 Nanoparticle Approaches 444
18.7 Conclusion 446
Acknowledgment 446
References 447
19 Receptor?]Mediated Drug Delivery 451
Chris V. Galliford and Philip S. Low
19.1 Introduction 451
19.2 Selection of a Receptor for Drug Delivery 454
19.3 Design of a Ligand-Drug Conjugate 455
19.4 Folate?]Mediated Drug Delivery 458
19.5 Conclusions 467
Acknowledgments 467
References 467
20 Protein and Peptide Conjugates for Targeting Therapeutics and Diagnostics to Specific Cells 475
Barlas Büyüktimkin, John Stewart, Jr., Kayann Tabanor, Paul Kiptoo, and Teruna J. Siahaan
20.1 Introduction 475
20.2 Radiolabeled Antibodies for Cancer Treatment 479
20.3 Antibody-Drug Conjugate 480
20.4 Non?]Antibody?]Based Protein-Drug Conjugates 486
20.5 Peptibody 488
20.6 Protein Conjugates for Diagnostics 489
20.7 Peptide-Drug Conjugates 491
20.8 Challenges in Analyzing Conjugates 494
20.9 Conclusions 497
References 497
21 Drug Delivery to the Lymphatic System 503
Qiuhong Yang and Laird Forrest
21.1 Introduction 503
21.2 Anatomy and Physiology of the Lymphatic System 504
21.3 Influence of Physicochemical Characteristics of Drug Carriers on Lymphatic Uptake and Transport 509
21.4 Carriers for Lymphatic Drug Delivery 513
21.5 Administration Routes for Lymphatic Delivery 528
21.6 Lymphatic?]Targeting Vaccination 536
21.7 Conclusions 538
References 539
22 The Development of Cancer Theranostics: A New Emerging Tool Toward Personalized Medicine 549
Hongying Su, Yun Zeng, Gang Liu, and Xiaoyuan Chen
22.1 Introduction 549
22.2 Imaging?]Guided Drug Delivery and Therapy 551
22.3 Optical Imaging-Based Theranostics 553
22.4 MRI?]Based Theranostics 558
22.5 Nuclear Imaging-Based Theranostics 559
22.6 Ultrasound?]Based Theranostic Platform 563
22.7 Multimodality Imaging-Based Theranostic Platform 564
22.8 Conclusion and Future Perspectives 567
Acknowledgments 569
References 569
23 Intracellular Delivery of Proteins and Peptides 576
Can Sarisozen and Vladimir P. Torchilin
23.1 Introduction 576
23.2 Intracellular Delivery Strategies of Peptides and Proteins 579
23.3 Concepts in Intracellular Peptide and Protein Delivery 580
23.4 Peptide and Protein Delivery to Lysosomes 589
23.5 Receptor?]Mediated Intracellular Delivery of Peptides and Proteins 590
23.6 Transmembrane Delivery of Peptides and Proteins 595
23.7 Conclusion 602
References 602
24 Vaccine Delivery: Current Routes of Administration and Novel Approaches 623
Neha Sahni, Yuan Cheng, C. Russell Middaugh, and David B. Volkin
24.1 Introduction 623
24.2 Parenteral Administration of Vaccines 625
24.3 Oral Delivery of Vaccines 634
24.4 Nasal and Aerosol Delivery of Vaccines 639
24.5 Conclusions 643
References 644
25 Delivery of Genes and Oligonucleotides 655
Charles M. Roth
25.1 Introduction 655
25.2 Systemic Delivery Barriers 656
25.3 Cellular Delivery Barriers 663
25.4 Current and Future Approaches to Nucleic Acid Delivery 666
25.5 Summary and Future Directions 668
References 668
Index 674
Preface xxi
1 Factors that Impact the Developability of Drug Candidates 1
Chao Han and Binghe Wang
1.1 Challenges Facing the Pharmaceutical Industry 1
1.2 Factors that Impact Developability 5
1.3 Remarks on Developability 12
1.4 Drug Delivery Factors that Impact Developability 13
References 15
2 Physiological, Biochemical, and Chemical Barriers to Oral Drug Delivery 19
Paul Kiptoo, Anna M. Calcagno, and Teruna J. Siahaan
2.1 Introduction 19
2.2 Physiological Barriers to Drug Delivery 20
2.3 Biochemical Barriers to Drug Delivery 25
2.4 Chemical Barriers to Drug Delivery 28
2.5 Drug Modifications to Enhance Transport Across Biological Barriers 29
2.6 Conclusions 31
Acknowledgment 31
References 31
3 Physicochemical Properties, Formulation, and Drug Delivery 35
Dewey H. Barich, Mark T. Zell, and Eric J. Munson
3.1 Introduction 35
3.2 Physicochemical Properties 36
3.3 Formulations 42
3.4 Drug Delivery 43
3.5 Conclusion 47
References 47
4 Targeted Bioavailability: A Fresh Look at Pharmacokinetic and Pharmacodynamic Issues in Drug Discovery and Development 49
Christine Xu
4.1 Introduction 49
4.2 Target Bioavailability 50
4.3 Drug Delivery Trends and Targets Related to PK and PD 51
4.4 PK-PD in Drug Discovery and Development 51
4.5 Source of Variability of Drug Response 55
4.6 Recent Development and Issues of Bio?]Analytical Methodology 57
4.7 Mechanistic PK-PD Models 58
4.8 Summary 60
References 60
5 The Role of Transporters in Drug Delivery and Excretion 62
Marilyn E. Morris and Xiaowen Guan
5.1 Introduction 62
5.2 Drug Transport in Absorption and Excretion 63
5.3 ABC (ATP?]Binding Cassette) Transporter Family 67
5.4 SlC (Solute Carrier) Transporter Family 76
5.5 Conclusions 88
Acknowledgment 88
References 89
6 Intracellular Delivery and Disposition of Small?]Molecular?]Weight Drugs 103
Jeffrey P. Krise
6.1 Introduction 103
6.2 The Relationship between the Intracellular Distribution of a Drug and its Activity 104
6.3 The Relationship between the Intracellular Distribution of a Drug and its Pharmacokinetic Properties 104
6.4 Overview of Approaches to Study Intracellular Drug Disposition 105
6.5 The Accumulation of Drugs in Mitochondria, Lysosomes, and Nuclei 108
6.6 Summary and Future Directions 123
References 124
7 Cell Culture Models for Drug Transport Studies 131
Irina Kalashnikova, Norah Albekairi, Shariq Ali, Sanaalarab Al Enazy, and Erik Rytting
7.1 Introduction 131
7.2 General Considerations 132
7.3 Intestinal Epithelium 133
7.4 The Blood-Brain Barrier 135
7.5 Nasal and Pulmonary Epithelium 137
7.6 The Ocular Epithelial and Endothelial Barriers 141
7.7 The Placental Barrier 142
7.8 The Renal Epithelium 143
7.9 3D In Vitro Models 145
7.10 Conclusions 146
References 146
8 Intellectual Property and Regulatory Issues in Drug Delivery Research 152
Shahnam Sharareh and Wansheng Jerry Liu
8.1 Introduction 152
8.2 Pharmaceutical Patents 153
8.3 Statutory Requirements for Obtaining a Patent 154
8.4 Patent Procurement Strategies 157
8.5 Regulatory Regime 158
8.6 FDA Market Exclusivities 160
8.7 Regulatory and Patent Law Linkage 162
References 162
9 Presystemic and First?]Pass Metabolism 164
Qingping Wang and Meng Li
9.1 Introduction 164
9.2 Hepatic First?]Pass Metabolism 165
9.3 Intestinal First?]Pass Metabolism 170
9.4 Prediction of First?]Pass Metabolism 174
9.5 S trategies for Optimization of Oral Bioavailability 178
9.6 Summary 179
References 180
10 Pulmonary Drug Delivery: Pharmaceutical Chemistry and Aerosol Technology 186
Anthony J. Hickey
10.1 Introduction 186
10.2 Aerosol Technology 187
10.3 Disease Therapy 190
10.4 Formulation Variables 196
10.5 Regulatory Considerations 200
10.6 Future Developments 201
10.7 Conclusion 201
References 202
11 Transdermal Delivery of Drugs Using Patches and Patchless Delivery Systems 207
Tannaz Ramezanli, Krizia Karry, Zheng Zhang, Kishore Shah, and Bozena Michniak?]Kohn
11.1 Introduction 207
11.2 Transdermal Patch Delivery Systems 208
11.3 Patchless Transdermal Drug Delivery Systems 211
11.4 Recent Advances in Transdermal Drug Delivery 216
11.5 Summary 221
References 222
12 Prodrug Approaches to Drug Delivery 227
Longqin Hu
12.1 Introduction 227
12.2 Basic Concepts: Definition and Applications 228
12.3 Prodrug Design Considerations 238
12.4 Prodrugs of Various Functional Groups 241
12.5 Drug Release and Activation Mechanisms 258
12.6 Prodrugs and Intellectual Property Rights--Two Court Cases 266
References 268
13 Liposomes as Drug Delivery Vehicles 272
Guijun Wang
13.1 Introduction 272
13.2 Currently Approved Liposomal Drugs in Clinical Applications 273
13.3 Conventional and Stealth Liposomes 276
13.4 Stimuli?]Responsive Liposomes or Triggered?]Release Liposomes 277
13.5 Targeted Liposomal Delivery 289
13.6 Hybrid Liposome Drug Delivery System 291
13.7 Conclusions and Future Perspectives 293
References 293
14 Nanoparticles as Drug Delivery Vehicles 299
Dan Menasco and Qian Wang
14.1 Introduction 299
14.2 O rganic DDVs 308
14.3 Inorganic DDVs: Metal?] and Silica?]Based Systems 320
14.4 Conclusion 330
References 330
15 Evolution of Controlled Drug Delivery Systems 336
Krishnaveni Janapareddi, Bhaskara R. Jasti, and Xiaoling Li
15.1 Introduction 336
15.2 Biopharmaceutics and Pharmacokinetics 337
15.3 Material Science 341
15.4 Proteins, Peptides and Nucleic Acids 343
15.5 Discovery of New Molecular Targets--Targeted Drug Delivery 345
15.6 Microelectronics and Microfabrication Technologies 347
15.7 Conclusion 349
References 349
16 Pathways for Drug Delivery to the Central Nervous System 353
Ngoc H. On, Vinith Yathindranath, Zhizhi Sun, and Donald W. Miller
16.1 Introduction 353
16.2 Circumventing the CNS Barriers 356
16.3 Transient BBB Disruption 359
16.4 Transcellular Delivery Routes 364
16.5 Conclusions 375
References 375
17 Metabolic Activation and Drug Targeting 383
Xiangming Guan
17.1 Introduction 383
17.2 Anticancer Prodrugs and their Biochemical Basis 384
17.3 Antibody?] and Gene?]Directed Enzyme Prodrug Therapy 420
17.4 Summary 429
References 429
18 Targeted Delivery of Drugs to the Colon 435
Anil K. Philip and Sarah K. Zingales
18.1 Introduction 435
18.2 Microbially Triggered Release 437
18.3 pH?]Sensitive Polymers for Time?]Dependent Release 442
18.4 Osmotic Release 443
18.5 Pressure?]Controlled Delivery 443
18.6 Nanoparticle Approaches 444
18.7 Conclusion 446
Acknowledgment 446
References 447
19 Receptor?]Mediated Drug Delivery 451
Chris V. Galliford and Philip S. Low
19.1 Introduction 451
19.2 Selection of a Receptor for Drug Delivery 454
19.3 Design of a Ligand-Drug Conjugate 455
19.4 Folate?]Mediated Drug Delivery 458
19.5 Conclusions 467
Acknowledgments 467
References 467
20 Protein and Peptide Conjugates for Targeting Therapeutics and Diagnostics to Specific Cells 475
Barlas Büyüktimkin, John Stewart, Jr., Kayann Tabanor, Paul Kiptoo, and Teruna J. Siahaan
20.1 Introduction 475
20.2 Radiolabeled Antibodies for Cancer Treatment 479
20.3 Antibody-Drug Conjugate 480
20.4 Non?]Antibody?]Based Protein-Drug Conjugates 486
20.5 Peptibody 488
20.6 Protein Conjugates for Diagnostics 489
20.7 Peptide-Drug Conjugates 491
20.8 Challenges in Analyzing Conjugates 494
20.9 Conclusions 497
References 497
21 Drug Delivery to the Lymphatic System 503
Qiuhong Yang and Laird Forrest
21.1 Introduction 503
21.2 Anatomy and Physiology of the Lymphatic System 504
21.3 Influence of Physicochemical Characteristics of Drug Carriers on Lymphatic Uptake and Transport 509
21.4 Carriers for Lymphatic Drug Delivery 513
21.5 Administration Routes for Lymphatic Delivery 528
21.6 Lymphatic?]Targeting Vaccination 536
21.7 Conclusions 538
References 539
22 The Development of Cancer Theranostics: A New Emerging Tool Toward Personalized Medicine 549
Hongying Su, Yun Zeng, Gang Liu, and Xiaoyuan Chen
22.1 Introduction 549
22.2 Imaging?]Guided Drug Delivery and Therapy 551
22.3 Optical Imaging-Based Theranostics 553
22.4 MRI?]Based Theranostics 558
22.5 Nuclear Imaging-Based Theranostics 559
22.6 Ultrasound?]Based Theranostic Platform 563
22.7 Multimodality Imaging-Based Theranostic Platform 564
22.8 Conclusion and Future Perspectives 567
Acknowledgments 569
References 569
23 Intracellular Delivery of Proteins and Peptides 576
Can Sarisozen and Vladimir P. Torchilin
23.1 Introduction 576
23.2 Intracellular Delivery Strategies of Peptides and Proteins 579
23.3 Concepts in Intracellular Peptide and Protein Delivery 580
23.4 Peptide and Protein Delivery to Lysosomes 589
23.5 Receptor?]Mediated Intracellular Delivery of Peptides and Proteins 590
23.6 Transmembrane Delivery of Peptides and Proteins 595
23.7 Conclusion 602
References 602
24 Vaccine Delivery: Current Routes of Administration and Novel Approaches 623
Neha Sahni, Yuan Cheng, C. Russell Middaugh, and David B. Volkin
24.1 Introduction 623
24.2 Parenteral Administration of Vaccines 625
24.3 Oral Delivery of Vaccines 634
24.4 Nasal and Aerosol Delivery of Vaccines 639
24.5 Conclusions 643
References 644
25 Delivery of Genes and Oligonucleotides 655
Charles M. Roth
25.1 Introduction 655
25.2 Systemic Delivery Barriers 656
25.3 Cellular Delivery Barriers 663
25.4 Current and Future Approaches to Nucleic Acid Delivery 666
25.5 Summary and Future Directions 668
References 668
Index 674
Binghe Wang, PhD, is Regents' Professor of Chemistry and Associate Dean for Natural and Computational Sciences at Georgia State University as well as Georgia Research Alliance Eminent Scholar in Drug Discovery. He is Editor-in-Chief of the journal Medicinal Research Review and founding series editor of the Wiley Series in Drug Discovery and Development. He has published over 230 papers in medicinal chemistry, pharmaceutical chemistry, new diagnostics, and chemosensing.
Longqin Hu, PhD, is Professor of Medicinal Chemistry and Director of the Graduate Program in Medicinal Chemistry at Rutgers University. Among his major research interests are the synthesis and evaluation of anticancer prodrugs for the targeted activation in tumor tissues and the discovery of novel small molecule inhibitors of protein-protein interactions. He has published over 80 papers and 8 patents in bioorganic and medicinal chemistry.
Teruna Siahaan, PhD, is a Professor and Associate Chair of the Department of Pharmaceutical Chemistry and serves as the Director of the NIH Biotechnology Training Program at the University of Kansas. In addition to co-editing the first edition of Drug Delivery, he has written almost 195 journal papers and book chapters and received the 2014 PhRMA Foundation Award in Excellence in Pharmaceutics.
Longqin Hu, PhD, is Professor of Medicinal Chemistry and Director of the Graduate Program in Medicinal Chemistry at Rutgers University. Among his major research interests are the synthesis and evaluation of anticancer prodrugs for the targeted activation in tumor tissues and the discovery of novel small molecule inhibitors of protein-protein interactions. He has published over 80 papers and 8 patents in bioorganic and medicinal chemistry.
Teruna Siahaan, PhD, is a Professor and Associate Chair of the Department of Pharmaceutical Chemistry and serves as the Director of the NIH Biotechnology Training Program at the University of Kansas. In addition to co-editing the first edition of Drug Delivery, he has written almost 195 journal papers and book chapters and received the 2014 PhRMA Foundation Award in Excellence in Pharmaceutics.
